Hospital
ST Lukes Regional Medical Center
ST Lukes Regional Medical Center was paid $24.98M by Medicaid between Jan 2018 and Dec 2024, across 512 billing codes. Its largest line is 42820, Tonsillectomy and adenoidectomy; younger than age 12 — 10% of everything it billed.
33Billing provider infoST LUKES REGIONAL MEDICAL CENTER
BOISE, ID 83712
BOISE, ID 83712
33aNPI1770586794assigned 05/23/2005
33bProvider typeRehabilitation Hospital Unit
28Total paid$24.98M
24GClaims1,182,141
24DCodes billed512
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FOWLER, KATHRYN controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 391,142 | $9.30M | |
| 2019 | 375,777 | $9.43M | |
| 2020 | 209,212 | $4.97M | |
| 2021 | 51,624 | $358K | |
| 2022 | 61,298 | $384K | |
| 2023 | 56,375 | $285K | |
| 2024incomplete | 36,713 | $238K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 10% | 979 | 966 | $2.51M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 7.7% | 756 | 649 | $1.93M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 7.0% | 25,735 | 10,061 | $1.74M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 5.8% | 86,012 | 64,431 | $1.46M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.9% | 22,066 | 7,637 | $1.23M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 4.5% | 1,007 | 998 | $1.12M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.0% | 5,930 | 5,609 | $755K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 19,455 | 8,133 | $526K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 1.7% | 7,151 | 6,228 | $421K |
| 80053 | Comprehensive metabolic panel | 1.7% | 62,872 | 51,958 | $414K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 82,292 | 64,988 | $410K |
| 42830 | 1.6% | 263 | 262 | $396K |
500 more codes
| J9312 | Injection, rituximab, 10 mg | 1.5% | 205 | $385K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.4% | 342 | $350K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 10,182 | $316K |
| 99284 | Emergency room visit (serious) | 1.2% | 5,715 | $308K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 4,194 | $273K |
| J9310 | Injection, rituximab, 100 mg | 1.0% | 148 | $259K |
| J0897 | Injection, denosumab, 1 mg | <1% | 447 | $209K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,839 | $205K |
| 92523 | <1% | 1,406 | $199K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,397 | $192K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,253 | $191K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,780 | $188K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,876 | $186K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,864 | $176K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,779 | $175K |
| 92526 | <1% | 2,727 | $161K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,522 | $157K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,461 | $155K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,789 | $153K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,035 | $144K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,085 | $140K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,139 | $140K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,863 | $129K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,870 | $122K |
| 62322 | <1% | 245 | $116K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,255 | $116K |
| 97162 | <1% | 3,049 | $113K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,532 | $111K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 32 | $110K |
| 36415 | Collection of venous blood by venipuncture | <1% | 69,448 | $110K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 207 | $105K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,718 | $102K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,317 | $99K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,339 | $99K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,268 | $96K |
| 76830 | Ultrasound, transvaginal | <1% | 1,553 | $92K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,392 | $89K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 484 | $89K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,079 | $87K |
| 97116 | <1% | 4,362 | $85K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 707 | $77K |
| 80061 | Lipid panel | <1% | 9,271 | $75K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 890 | $75K |
| G0378 | Hospital observation service, per hour | <1% | 2,521 | $74K |
| 44970 | <1% | 25 | $74K | |
| 70496 | <1% | 675 | $74K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,814 | $73K |
| 76770 | <1% | 1,336 | $70K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,400 | $68K |
| 97161 | <1% | 1,341 | $68K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,897 | $65K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 879 | $63K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,277 | $62K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,083 | $62K |
| 47562 | <1% | 26 | $61K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,840 | $61K |
| 83690 | <1% | 12,967 | $60K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,585 | $60K |
| 97166 | <1% | 1,107 | $59K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 161 | $58K |
| 84484 | <1% | 10,940 | $55K | |
| 70498 | <1% | 540 | $54K | |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 89 | $53K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,120 | $53K |
| 97163 | <1% | 1,440 | $52K | |
| 72141 | <1% | 601 | $52K | |
| 92609 | <1% | 767 | $51K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 285 | $50K |
| 84439 | <1% | 6,599 | $49K | |
| 87077 | <1% | 7,637 | $49K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,196 | $49K |
| 87081 | <1% | 7,129 | $47K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,330 | $47K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 740 | $46K |
| 83880 | <1% | 3,257 | $46K | |
| 87641 | <1% | 1,691 | $45K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 245 | $45K |
| 87640 | <1% | 1,682 | $45K | |
| 81001 | <1% | 20,451 | $44K | |
| 81025 | <1% | 6,992 | $43K | |
| 97750 | <1% | 1,071 | $42K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,503 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,113 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,826 | $41K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18,781 | $38K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,556 | $37K |
| 83605 | <1% | 5,958 | $37K | |
| 74018 | <1% | 2,837 | $36K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,895 | $36K |
| 82728 | <1% | 3,595 | $36K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 852 | $36K |
| 73630 | <1% | 2,732 | $36K | |
| 77066 | Tomosynthesis, mammo | <1% | 506 | $35K |
| 83970 | <1% | 1,385 | $35K | |
| 76801 | <1% | 621 | $34K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,747 | $34K |
| 83735 | <1% | 7,872 | $33K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 670 | $33K |
| 87505 | <1% | 299 | $33K | |
| 80306 | <1% | 3,199 | $32K | |
| 76642 | <1% | 1,020 | $32K | |
| 73610 | <1% | 2,161 | $31K | |
| 87186 | <1% | 5,234 | $30K | |
| 84702 | <1% | 2,051 | $30K | |
| 73564 | <1% | 1,810 | $30K | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | <1% | 28 | $29K |
| 80047 | <1% | 3,116 | $29K | |
| 80076 | <1% | 3,836 | $29K | |
| 86140 | <1% | 9,215 | $29K | |
| 87040 | <1% | 3,609 | $28K | |
| 86003 | <1% | 447 | $28K | |
| 71250 | <1% | 640 | $28K | |
| 74230 | <1% | 446 | $27K | |
| 92611 | <1% | 462 | $27K | |
| 74183 | <1% | 190 | $27K | |
| 70491 | <1% | 303 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 16,875 | $26K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 517 | $26K |
| 86703 | <1% | 2,003 | $26K | |
| 86762 | <1% | 1,962 | $25K | |
| 92610 | <1% | 470 | $25K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 329 | $25K |
| 82784 | <1% | 2,018 | $25K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 167 | $24K |
| 86850 | <1% | 3,556 | $24K | |
| 87340 | <1% | 2,378 | $23K | |
| 85379 | <1% | 3,772 | $23K | |
| 73110 | <1% | 1,274 | $23K | |
| 97760 | <1% | 882 | $23K | |
| 72082 | <1% | 727 | $23K | |
| 84481 | <1% | 1,629 | $22K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,360 | $22K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,928 | $21K |
| 87506 | <1% | 123 | $21K | |
| 42821 | <1% | 12 | $21K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 556 | $21K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 845 | $21K |
| 83615 | <1% | 3,774 | $21K | |
| 20680 | <1% | 12 | $20K | |
| 70486 | <1% | 324 | $20K | |
| 83516 | <1% | 1,806 | $20K | |
| 73130 | <1% | 1,242 | $20K | |
| 82607 | <1% | 2,230 | $19K | |
| 84100 | <1% | 5,286 | $19K | |
| 73221 | <1% | 183 | $19K | |
| 82962 | <1% | 9,843 | $19K | |
| 73502 | <1% | 1,244 | $19K | |
| 87070 | <1% | 2,721 | $19K | |
| 73030 | <1% | 1,719 | $18K | |
| 85610 | <1% | 8,618 | $18K | |
| 84403 | <1% | 928 | $18K | |
| 82533 | <1% | 797 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,100 | $17K |
| 84550 | <1% | 4,126 | $17K | |
| 72100 | <1% | 1,290 | $17K | |
| 76536 | <1% | 306 | $17K | |
| 77065 | Tomosynthesis, mammo | <1% | 326 | $16K |
| 86803 | <1% | 1,606 | $16K | |
| 97165 | <1% | 310 | $16K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 32,199 | $16K |
| 87420 | <1% | 1,191 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,078 | $16K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 136 | $16K |
| 82803 | <1% | 908 | $15K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,427 | $15K |
| 81003 | <1% | 9,088 | $15K | |
| 85652 | <1% | 8,102 | $14K | |
| 97167 | <1% | 290 | $14K | |
| 73140 | <1% | 776 | $14K | |
| 73090 | <1% | 979 | $14K | |
| 84305 | <1% | 700 | $13K | |
| 76813 | <1% | 289 | $13K | |
| 64721 | <1% | 13 | $13K | |
| 76942 | <1% | 741 | $12K | |
| 83001 | <1% | 684 | $12K | |
| 83550 | <1% | 1,948 | $12K | |
| 73100 | <1% | 733 | $12K | |
| 73080 | <1% | 782 | $12K | |
| 86901 | <1% | 4,144 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,977 | $12K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,323 | $12K |
| 72170 | <1% | 774 | $11K | |
| 86235 | <1% | 171 | $11K | |
| 83540 | <1% | 2,546 | $11K | |
| 90715 | <1% | 877 | $11K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 111 | $11K |
| 86593 | <1% | 2,611 | $11K | |
| 84703 | <1% | 1,464 | $10K | |
| 73590 | <1% | 837 | $10K | |
| 86900 | <1% | 3,643 | $10K | |
| 82746 | <1% | 1,043 | $10K | |
| 82570 | <1% | 3,711 | $10K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 109 | $10K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,799 | $9K |
| 36416 | <1% | 3,300 | $9K | |
| 86160 | <1% | 479 | $9K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,249 | $9K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 142 | $9K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,569 | $9K |
| 73070 | <1% | 609 | $9K | |
| 84146 | <1% | 521 | $9K | |
| 72040 | <1% | 699 | $9K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 160 | $9K |
| 97763 | <1% | 236 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,964 | $9K |
| 76820 | <1% | 496 | $9K | |
| 80197 | <1% | 1,185 | $9K | |
| 82950 | <1% | 1,808 | $9K | |
| 73560 | <1% | 591 | $9K | |
| 86376 | <1% | 695 | $9K | |
| 84153 | <1% | 796 | $9K | |
| 80074 | <1% | 187 | $8K | |
| 87205 | <1% | 2,631 | $8K | |
| 85730 | <1% | 1,765 | $8K | |
| 82670 | <1% | 353 | $8K | |
| 72146 | <1% | 88 | $8K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 466 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,330 | $7K |
| 80069 | <1% | 1,224 | $7K | |
| 82550 | <1% | 1,511 | $7K | |
| 77080 | <1% | 728 | $7K | |
| J3490 | Unclassified drugs | <1% | 59 | $7K |
| 73562 | <1% | 466 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,082 | $6K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 2,822 | $6K |
| 82731 | <1% | 95 | $6K | |
| 87449 | <1% | 629 | $6K | |
| 80164 | <1% | 630 | $6K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 164 | $6K |
| 86481 | <1% | 79 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,691 | $6K |
| G0008 | Administration of influenza virus vaccine | <1% | 2,906 | $6K |
| 72081 | <1% | 317 | $6K | |
| 29581 | <1% | 1,526 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 522 | $6K |
| 96415 | <1% | 191 | $6K | |
| 86038 | <1% | 641 | $6K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 845 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,454 | $5K |
| 74022 | <1% | 321 | $5K | |
| 86800 | <1% | 401 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 205 | $5K |
| 82247 | <1% | 936 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,560 | $5K |
| 87324 | <1% | 543 | $5K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 899 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,739 | $5K |
| 78227 | <1% | 15 | $5K | |
| 87486 | <1% | 161 | $5K | |
| 87581 | <1% | 161 | $5K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 243 | $5K |
| 97164 | <1% | 152 | $5K | |
| 72070 | <1% | 366 | $5K | |
| 73552 | <1% | 322 | $5K | |
| 82043 | <1% | 1,871 | $5K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 184 | $5K |
| 86920 | <1% | 243 | $5K | |
| 84156 | <1% | 1,593 | $4K | |
| 83002 | <1% | 389 | $4K | |
| 72131 | <1% | 76 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 129 | $4K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,406 | $4K |
| 83520 | <1% | 292 | $4K | |
| 92522 | <1% | 58 | $4K | |
| 82378 | <1% | 309 | $4K | |
| 84480 | <1% | 309 | $4K | |
| 87210 | <1% | 919 | $4K | |
| 76885 | <1% | 85 | $4K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 26 | $4K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,169 | $4K |
| 82024 | <1% | 133 | $4K | |
| 82951 | <1% | 295 | $4K | |
| 76870 | <1% | 161 | $4K | |
| 72156 | <1% | 25 | $4K | |
| 82977 | <1% | 539 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 267 | $4K |
| 82010 | <1% | 551 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 254 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,960 | $4K |
| 82140 | <1% | 290 | $3K | |
| 74178 | <1% | 26 | $3K | |
| 97032 | <1% | 259 | $3K | |
| 82105 | <1% | 230 | $3K | |
| 82565 | <1% | 898 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 991 | $3K |
| 71101 | <1% | 213 | $3K | |
| 86706 | <1% | 341 | $3K | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 59 | $3K |
| 73522 | <1% | 146 | $3K | |
| 87660 | <1% | 120 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,952 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,449 | $3K |
| 85045 | <1% | 710 | $3K | |
| 82077 | <1% | 875 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,417 | $3K |
| 77072 | <1% | 290 | $3K | |
| 83993 | <1% | 126 | $3K | |
| 51798 | <1% | 1,311 | $3K | |
| 97597 | <1% | 200 | $2K | |
| 83525 | <1% | 199 | $2K | |
| 89051 | <1% | 520 | $2K | |
| 82397 | <1% | 166 | $2K | |
| 85046 | <1% | 441 | $2K | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | <1% | 15 | $2K |
| 87510 | <1% | 120 | $2K | |
| 87480 | <1% | 120 | $2K | |
| 77001 | <1% | 83 | $2K | |
| 87430 | <1% | 162 | $2K | |
| 72158 | <1% | 13 | $2K | |
| 52000 | <1% | 55 | $2K | |
| 73000 | <1% | 162 | $2K | |
| 96376 | <1% | 1,417 | $2K | |
| 84165 | <1% | 416 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 899 | $2K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 146 | $2K |
| 86431 | <1% | 423 | $2K | |
| 20610 | <1% | 917 | $2K | |
| 84134 | <1% | 232 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,042 | $2K |
| 72157 | <1% | 12 | $2K | |
| 87799 | <1% | 61 | $2K | |
| 84466 | <1% | 176 | $2K | |
| 82785 | <1% | 175 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 713 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 65 | $2K |
| 85018 | <1% | 1,207 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 337 | $2K |
| 84402 | <1% | 74 | $2K | |
| 93971 | <1% | 64 | $2K | |
| J9175 | Injection, elliotts' b solution, 1 ml | <1% | 182 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 373 | $2K |
| 74240 | <1% | 30 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 901 | $2K |
| 74455 | <1% | 28 | $1K | |
| 92557 | <1% | 163 | $1K | |
| 73120 | <1% | 107 | $1K | |
| 82947 | <1% | 222 | $1K | |
| 82150 | <1% | 277 | $1K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 505 | $1K |
| 86039 | <1% | 138 | $1K | |
| 86147 | <1% | 40 | $1K | |
| 87075 | <1% | 146 | $1K | |
| 80178 | <1% | 241 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,756 | $1K |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 14 | $1K |
| 93296 | <1% | 372 | $1K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 227 | $1K |
| 73660 | <1% | 110 | $1K | |
| 85014 | <1% | 733 | $1K | |
| 87015 | <1% | 163 | $1K | |
| 86255 | <1% | 80 | $972.89 | |
| 86225 | <1% | 78 | $963.26 | |
| 84145 | <1% | 51 | $960.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 560 | $952.04 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 426 | $940.65 |
| 90686 | <1% | 818 | $933.61 | |
| 76775 | <1% | 46 | $924.28 | |
| 64615 | <1% | 170 | $922.13 | |
| 86200 | <1% | 87 | $920.97 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 485 | $908.53 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 16 | $907.97 |
| 86256 | <1% | 72 | $904.69 | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 55 | $887.88 |
| 82310 | <1% | 234 | $866.85 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,070 | $829.25 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 4,030 | $798.28 |
| 86704 | <1% | 90 | $777.64 | |
| 87338 | <1% | 53 | $745.88 | |
| 77073 | <1% | 49 | $743.41 | |
| 83721 | <1% | 89 | $735.84 | |
| 73060 | <1% | 61 | $723.26 | |
| 80175 | <1% | 76 | $707.57 | |
| 84425 | <1% | 41 | $687.83 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 59 | $677.12 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 33 | $674.42 |
| 90656 | <1% | 477 | $638.36 | |
| 0450 | Emergency room services | <1% | 20 | $629.78 |
| 76937 | <1% | 91 | $625.94 | |
| 90662 | <1% | 831 | $611.43 | |
| 73620 | <1% | 58 | $607.32 | |
| 90670 | <1% | 26 | $602.04 | |
| 86360 | <1% | 13 | $558.00 | |
| 87522 | Neg quan hep c or qual rna | <1% | 28 | $540.95 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 753 | $540.54 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 631 | $537.38 |
| 86308 | <1% | 102 | $525.91 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 296 | $510.02 |
| 87102 | <1% | 66 | $501.74 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 195 | $487.31 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 131 | $482.31 |
| 72110 | <1% | 26 | $459.85 | |
| 86359 | <1% | 13 | $455.13 | |
| 86665 | <1% | 12 | $443.52 | |
| 77336 | <1% | 29 | $438.40 | |
| J9250 | Methotrexate sodium, 5 mg | <1% | 304 | $430.81 |
| 93922 | <1% | 44 | $430.47 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 283 | $427.64 |
| 90732 | <1% | 87 | $420.05 | |
| 82248 | <1% | 109 | $415.08 | |
| 82627 | <1% | 29 | $413.02 | |
| C1769 | Guide wire | <1% | 541 | $405.29 |
| 99152 | <1% | 192 | $398.36 | |
| J2400 | Injection, chloroprocaine hydrochloride, per 30 ml | <1% | 18 | $378.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 855 | $354.59 |
| 82139 | <1% | 24 | $338.28 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 201 | $322.69 |
| 74019 | <1% | 19 | $318.60 | |
| 84630 | <1% | 39 | $316.75 | |
| 84590 | <1% | 29 | $301.73 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 33 | $296.69 |
| 73600 | <1% | 12 | $295.97 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 588 | $294.94 |
| 84270 | <1% | 18 | $282.59 | |
| 80143 | <1% | 206 | $280.97 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,358 | $275.01 |
| 73521 | <1% | 14 | $258.58 | |
| 94726 | <1% | 74 | $255.68 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 157 | $251.17 |
| 83789 | <1% | 14 | $238.70 | |
| 82379 | <1% | 17 | $232.34 | |
| 82274 | <1% | 14 | $229.84 | |
| 96367 | <1% | 36 | $228.07 | |
| 83883 | <1% | 24 | $222.85 | |
| 82952 | <1% | 60 | $218.92 | |
| 85240 | <1% | 13 | $218.79 | |
| 76882 | <1% | 13 | $218.72 | |
| 77002 | <1% | 12 | $218.08 | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 130 | $214.93 |
| 80179 | <1% | 193 | $212.18 | |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 626 | $210.18 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 558 | $205.11 |
| 85027 | <1% | 238 | $186.68 | |
| 36600 | <1% | 13 | $186.62 | |
| 70360 | <1% | 16 | $184.78 | |
| 83655 | <1% | 27 | $184.57 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 105 | $183.56 |
| 93017 | <1% | 13 | $182.32 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 35 | $181.52 |
| 86304 | <1% | 14 | $175.04 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 18 | $173.60 |
| 84446 | <1% | 12 | $163.74 | |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | <1% | 13 | $154.14 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 53 | $148.51 |
| 94010 | <1% | 12 | $145.91 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 241 | $142.21 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 76 | $136.04 |
| 82330 | <1% | 14 | $124.82 | |
| 89050 | <1% | 35 | $123.75 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 1,258 | $121.19 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 51 | $119.46 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 1,121 | $117.63 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 33 | $109.29 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 60 | $107.50 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 387 | $78.48 |
| 93280 | <1% | 12 | $72.49 | |
| A9270 | Non-covered item or service | <1% | 6,927 | $68.26 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 572 | $67.48 |
| 91320 | <1% | 123 | $56.08 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 69 | $55.94 |
| 36591 | <1% | 214 | $48.18 | |
| 80050 | General health panel | <1% | 543 | $47.62 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,039 | $39.12 |
| 84132 | <1% | 12 | $35.98 | |
| 96112 | <1% | 14 | $34.19 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 3,525 | $33.75 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 85 | $33.52 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 12 | $32.23 |
| 88342 | <1% | 45 | $28.35 | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 12 | $23.29 |
| 94729 | <1% | 106 | $23.10 | |
| 81002 | <1% | 104 | $20.91 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 57 | $14.88 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 307 | $11.47 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 167 | $9.03 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 164 | $9.03 |
| 87071 | <1% | 40 | $5.22 | |
| A6252 | Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 148 | $4.88 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 14 | $3.70 |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 65 | $2.69 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $0.45 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 15 | $0.00 |
| 0094A | 0% | 34 | $0.00 | |
| 99406 | 0% | 44 | $0.00 | |
| 92567 | 0% | 14 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 12 | $0.00 |
| 90480 | 0% | 123 | $0.00 | |
| 94761 | 0% | 14 | $0.00 | |
| 97130 | 0% | 30 | $0.00 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 17 | $0.00 |
| 97533 | 0% | 91 | $0.00 | |
| 97127 | 0% | 41 | $0.00 | |
| S4990 | Nicotine patches, legend | 0% | 28 | $0.00 |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 64 | $0.00 |
| 0054A | 0% | 13 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 13 | $0.00 |
| 97129 | 0% | 43 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 243 | $0.00 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 12 | $0.00 |
| 94060 | 0% | 12 | $0.00 | |
| 0124A | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOWLER, KATHRYN (SENIOR VP, CFO)
Parent organizationST LUKES HEALTH SYSTEM LTD
| Provider | Location | Paid |
|---|---|---|
| ST Lukes Clinic-Treasure Valley LLC | Boise, ID | $59.26M |
| ST Luke's Clinic LLC | Twin Falls, ID | $39.50M |
| ST. Luke's Magic Valley Regional Medical Center, LTD. | Twin Falls, ID | $7.95M |
| ST Lukes Clinic-Treasure Valley LLC | Mountain Home, ID | $6.86M |
| Magic Valley Paramedics L L C | Twin Falls, ID | $4.57M |
| ST Lukes Clinic-Treasure Valley LLC | Baker City, OR | $2.08M |
| ST Lukes Nampa Medical Center LTD | Nampa, ID | $1.87M |
| ST Luke's Regional Medical Center | Meridian, ID | $1.55M |
| ST Lukes Regional Medical Center | Mountain Home, ID | $942K |
| ST Lukes Clinic - Wood River LLC | Ketchum, ID | $717K |
| ST Luke's Magic Valley Regional Medical Center LTD | Jerome, ID | $577K |
| ST Lukes Clinic - Mccall LLC | Mccall, ID | $576K |
| ST Luke's Regional Medical Center | Meridian, ID | $397K |
| ST. Luke's Magic Valley Regional Medical Center LTD | Twin Falls, ID | $300K |
| ST Lukes Wood River Medical Center LTD | Ketchum, ID | $174K |
| ST Lukes Mccall LTD | Mccall, ID | $149K |
| ST Lukes Regional Medical Center | Boise, ID | $49K |
| ST Lukes Magic Valley Regional Medical Center LTD | Twin Falls, ID | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.